A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs).
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TACT-2C
- 16 Feb 2018 Status changed from recruiting to discontinued.
- 01 Apr 2015 New trial record